Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Oncogene deal

Robert Van Nostrand, vice president of finance and administration at ONCS, said the chemoprotectant agent will enter the

Read the full 183 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE